Silence Therapeutics plc (LSE: SLN) is a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases.
The company possesses one of the most comprehensive and sophisticated RNAi therapeutic platforms comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features – the three areas the company believes to be critical to building, protecting and commercializing RNAi therapeutics. This platform is protected by Silence’s strong intellectual property portfolio which includes more than 200 issued and pending patent applications worldwide.
Additionally, Silence is a clear leader in the development of RNAi clinical candidates, possessing a pipeline that includes a total of five different internal and partnered programs in the clinic. With at least half of the siRNA programs currently in clinical development worldwide based on Silence's technology, the company’s clinical pipeline validates not only the strength of the company's proprietary technology but also the team of researchers that has guided the development path.
A final key validation of Silence’s leadership position in RNAi is the company’s multiple major partnerships with global pharmaceutical companies. The partnerships with companies such as AstraZeneca, Pfizer/Quark Pharma and Dainippon Sumitomo further demonstrate the credibility of Silence’s technologies.